key: cord-0926201-6k5ac3f2 authors: Junejo, Yasmeen; Ozaslan, Mehmet; Safdar, Muhamad; Khailany, Rozhgar A.; Rehman, SaifUr; Yousaf, Wasim; Khan, Musarrat Abbas title: Novel SARS-CoV-2/COVID-19: Origin, pathogenesis, genes and genetic variations, immune responses and phylogenetic analysis date: 2020-06-15 journal: Gene Rep DOI: 10.1016/j.genrep.2020.100752 sha: 81b0d92c0985702aec0c3504eeb304569cb04449 doc_id: 926201 cord_uid: 6k5ac3f2 In this review, we focused on the origins of the novel coronavirus (SARS-CoV-2), origin, pathogenesis, immune responses, genes and genetic variations, phylogenetic analyses, and potential therapeutic strategies to summarize approaches for developing broadly effective preventions and vaccines to cope COVID-19. Towards the end of 2019, SARS-CoV-2 has emerged in association with the SARS, later was named COVID-19 caused an environment of chaos worldwide and infected a massive number of lives. Since these epidemics or pandemics had spread to 210 countries and territories around the world and 2 international conveyances with 6,467,229 confirmed cases, including, 382,766 deaths, as of June 03, 2020 (https://www.worldometers.info/coronavirus/), hence the World Health Organization declared it as a global Public Health Emergency. There are no clinically approved vaccines or antiviral drugs available for either of new or old corona infections; thus, the development of effective therapeutic and preventive strategies that can be readily available to cope with these strains. Before December 2019, very little was known about the Coronaviruses (CoVs) because previously CoVs were not hit the global community so badly even though CoVs have been infected many species including humans and discussed for more than 70 years. Bailey et al [2] were reported murine virus (JHM) for the first time in 1949. Molecular mechanisms and pathogenesis of different CoVs have been intensely studied in different animal species such as porcine transmissible gastroenteritis virus (TGEV), bovine coronavirus (BCoV), and avian infectious bronchitis viruses (IBV). The CoVs having emergence and re-emergence history causing respiratory and intestinal infections in animals and humans [31] . This family of viruses remained unclear because they can only cause common cold symptoms in immune-competent individuals until the outbreak of severe acute respiratory syndrome (SARS) in 2003 [50] . Before the SARS epidemic in 2002-03, it was supposed that CoVs are not deadly pathogens to humans. Subsequently, a decade later in 2012, another Zoonotic highly pathogenic coronavirus emerged in Middle Eastern countries caused the Middle East respiratory syndrome (MERS) epidemic [59] . The ongoing SARS-CoV-2 pandemic situation got worldwide attention and became the utmost priority of the global health community due to the higher rate of human-human J o u r n a l P r e -p r o o f 3 transmission. Previous studies have confirmed that SARS-CoV-2 adopted recombination and mutations strategies that help to adapt rapidly changing host environments through genotype adjustment via reproductive adaptability and ultimately escape from human immune reconnaissance [41] . In a broader perspective, this review will describe the SARS-CoV-2 origins, epidemiology, pathogenesis, clinical manifestations, immune enhancement, genes and their variations, phylogenetic analyses, potential therapeutic strategies and future perspective to summarize approaches for developing broadly effective prevention of Corona Virus Disease-19 . Coronaviridae family divided into two subfamilies, the coronaviruses, and the toroviruses. All identified CoVs are categorized into four different genera alpha coronaviruses, beta coronaviruses, gammacoronaviruses, and delta coronaviruses. The human infecting CoVsbelongs to alpha coronaviruses and beta coronaviruses, whereas gammacoronaviruses, and delta coronaviruses showed susceptibility for fish and birds as shown in figure 1. All human infecting CoVs can cause mild to severe infection in humans and used spillover intermediate hosts ( Figure 2 ). Earlier to 2019, there were only six CoVs that were known to infect humans and cause respiratory diseases. Four out of six (HCoV-229E, HCoV-OC43, HCoV-NL63, and HKU1)human infecting CoVs can only cause mild upper respiratory disease, and in rare cases, some of them can cause severe infection in infants, young children, and elders ( Figure 2 ). Although, SARS-CoV and MERS-CoVwhich are zoonotic in origin can J o u r n a l P r e -p r o o f 4 infect the lower respiratory tract and cause a severe respiratory syndrome in humans [5, 6, 54] . Previously studied known pathogenic coronaviruses are presented in the table (Table 1) . SARS and the MERSCoVsbelong to beta coronaviruses have been characterized as they were transmitted from animals to humans and caused severe disease outbreaks in the past. SARS-CoVwastransmittedin humans from bats via the intermediary host of palm civet cats ( Figure 2 ) in the Guangdong province of China and about 8422 infected cases with 916 deaths were recorded and the mortality rate was 11%. Furthermore, a decade later in 2012, a bat origin virus MERS-CoVepidemic was emerged in Saudi Arabia through the dromedary camels ( Figure 2 ) and caused 858 deaths out of 2494 infected people with a 34% fatality rate [43] . Now, in late December 2019, a couple of patients were diagnosed with concentrated pneumonia with an unknown etiology in Wuhan, China [4, 24, 27] . The newly emerged novel CoV retained 99.8-99.9% nucleotide sequence homology with beta bat CoVs that directed the reemergence of another viral strain, later entitled as SARS-CoV-2 [39] and genetic analysis of the SARS-CoV-2 represented genetic similarity 50% with MERS-CoV and 80% with SARS-CoV [27, 39, 41] . As of 03 June 2020, a total of 6,467,229 cases of COVID-19 have been confirmed worldwide including 382,766 deaths (WHO, 2020).COVID-19 as an acute respiratory infectious disease, primarily spreads by the mean of the respiratory tract, via droplets, respiratory secretions emitted from an infected person or direct contact for a low infective dose [28, 29] . Significantly high level of viral loads was also observed in the nasal cavity as compared to the throat where the viral load was the same between symptomatic and asymptomatic people [60] . Patients can be J o u r n a l P r e -p r o o f 5 a career of infection even on clinical recovery and few people may act as a strong candidate to spread the infection, for example, an infected UK resident caused 11 people to infect by COVID- 19 . The incubation period of this disease ranges from 2 to 14 days (median 5 days) [43] . SARS-CoV-2 virus responds to the same receptor, angiotensin receptor 2 (ACE2), to enter the respiratory mucosa as the SARS-CoV entry receptor [8] . The SARS-CoV-2 is a respiratory system targeting virus therefore the prime pathogenesis of the COVID-19 severe pneumonia, RNAaemia, combined with the incidence of ground-glass opacities, and acute cardiac injury. Also, some patients were exhibited non-respiratory symptoms such as the acute liver and heart injury, kidney failure, diarrhea, implying multiple organ involvement [7, 18, 22, 23, 42, 51] . Crucially, viral replication is supposed to occur in the mucosal epithelium of the upper respiratory tract (nasal cavity and pharynx), in addition, proliferation is in the lower respiratory tract and gastrointestinal mucosa that results in the mild viremia [56, 57] . The clinical features of COVID-19 range from an asymptomatic condition to acute respiratory distress syndrome and multiple organ dysfunction, so it is difficult to distinguish it from other respiratory infections. Almost 5.2 days' time period of incubation is required for the appearance of COVID-19 symptoms [28] , and after one week of the onset of disease patients experience J o u r n a l P r e -p r o o f 6 injury can cause death [9, 35, 36] . The shorter period was witnessed in patients with the age of more than 70-years old [9] . Incompatible death results are more common in the elderly and those with underlying co-morbidities (50-75% of fatal cases). In the adult, aged patient's fatality rate ranges between 4 to 11% while the overall fatality rate varies between 2 to 3% [35, 38] . In another study, similar symptoms for COVID-19 and earlier betacoronavirus have been observed in chest CT scans [23] . Although, some distinctive clinical features in COVID-19 exist including lower airway and upper respiratory tract symptoms like rhinorrhea, sneezing, and throat soring [1, 30] . Similarly, chest radiography of some patients showed an infiltrate in the upper lobe of the patients [36] . Whereas, gastrointestinal symptoms like diarrhea were also diagnosed in some COVID-19 patients [20] , which were also found in MERS-CoV or SARS- Antibody-dependent enhancement (ADE) occurs when non-neutralizing antiviral proteins facilitate virus entry into host cells, leading to increased infectivity in the cells. Recently, ADE is proposed as a responsible for theinflammationbecause of SARS-CoV-2 infection [17] . ADE can interact with virus-antibody complexes their receptors, and increasing the target cell infection [47] . The interaction between specific recepter and virus complex can activate both pathways such as inflammatory responses and viral replication in the patients [20] . In another study, loss of ACE2 function is related to acute lung injury because the ACE2downregulation can result in RAS dysfunction, and endorse the inflammation that causes vascular permeability [25] . These Additionally, lymphopenia is also reported as a common characteristic of COVID-19 which is a serious reason account for severe infection and a higher rate of mortality [23, 58] . The virus can remain viable on surfaces in suitable conditions and can be smashed within 60 seconds by common disinfectants like sodium hypochlorite and hydrogen peroxide [26] . Interestingly -inflammatory cytokines including IL2, IL7, IL10, GCSF, IP10, MCP1, MIP1 α, and TNF α that were responsible for disease severity [23] . After genetic variability, the cytokines were studied and the incidence of ARDS was evidenced. Many candidate genes, i.e. ACE2, IL-10, TNF, VEGF are believed to be associated with ARDS development or outcome [33] . In addition, the increased levels of IL-6 and IL-8 were confirmed to be associated with ARDS [46] . The genetic information of any life is preserved in its genome, and the annotation is the first step (Table 2) . Moreover, they also presented nine putative recombinants in SARS-CoV-2 and hypothesized that SARS-CoV-2 is the recombinant of SARS and SARS-like CoVs. Six out of nine recombinants are in S motif which is important for viral pathogenicity. Furthermore, SARS-CoV-2 receptor-binding domain (RBD) was analyzed and showed 73% sequence similarity with the pandemic RBD [41] . While the binding free energies that were calculated for human ACE2 and S protein binding complexes and SARS-CoV-2 free binding energy increased up to 28 kcal mol -1 , representing higher binding affinity to the human ACE2 receptor [41] . Distinguishing the origins of an emerging pathogen can be critical during the beginning periods of an outbreak as it may allow for containment measures to be precisely targeted. Before China [44] . Coronaviruses are naturally hosted and developmentally formed by bats. To do this, it has been proposed that the majority of human coronaviruses are derived from the bat reservoir [48] . Several teams have recently confirmed the genetic similarity between SARS-CoV-2 and the beta betacorone virus of the subgenus Sarabacovirus [48] . The genome sequence of the new virus is 96.2% identical to that of the bat. SARS-related coronavirus (SARSr-CoV; RaTG13) has been collected in Wuhan, China, but is not identical to the genome of SARS-CoV (about 79%) or MERS-CoV (approximately) 50%) as shown in Figure 4 . Replacement and recombination of nucleotides has been proposed a mechanism of viral development in nature [41, 49] . In addition, SARS-CoV-2 uses the same receptor, angiotensin II converting enzyme (ACE2) as SARS-CoV. Although the specific pathway of transmission from natural reservoirs to humans is unclear [37, 48] , several studies have shown that pangolin may confer partial spike genes to SARS-CoV-2; The critical functional regions of the spike protein SAR-CoV-2 are nearly the same as those defined in viruses isolated from a pangolin [32, 48] . In the early era until 1960 CoVs were thought to be simple viruses causing flu-like symptoms. In later studies, it was proved that CoV is a more serious and dangerous virus and it causes SARS epidemics (2002 to 2003) [10, 28, 51] . Countries in 2012 posed a very serious condition that proved it more dangerous [3, 10, 28, 51] . To manage the COVID-19 antipyretics and analgesics are directed. Moreover, hydration is maintained and also the respiratory system is supported by mechanical ventilation or extracorporeal membrane oxygenation. In case of bacterial infection along with COVID-19 antibiotics are found beneficial. We may use chloroquine and hydroxychloroquine having Journal Pre-proof J o u r n a l P r e -p r o o f 10 synergistic effects, but further studies needed [13, 35] . Also, we have the option of Favipiravir and Remdesivir which were trialed by China and Japan but further studies are required [17, 21] . Also, many evidences showed that convalescent plasma from patients recovering from viral infections can be used as a treatment in patients infected with SARS-CoV-2 [12] . In addition, by influencing ACE2 levels, cardiovascular diseases and / or their treatment can play an important role in the infectivity and consequences of COVID -19. Whether ACE2 treatment or upregulation caused by the disease immediately affects the COVID -19 course [45] . During this global emergency of the COVID-19 pandemic, strategies are taken into account to quickly monitor the timeline for licensing a vaccine against COVID-19, especially by compressing the generally long duration of phase II-III study [11, 13, 15, 16] . It is widely accepted that there are many viruses in their natural reservoirs for a very long  The reemergence of SARS-CoV-2 got worlds attention due to its higher rate of human-human transmission as such there is no competent treatment is available to lesson the pandemic situation  SARS-CoV-2 belongs to beta coronaviruses that adopted different genomic level variations which help to find away from the human immune system  Moreover, clinically SARS-CoV-2 can cause mild to severe respiratory tract infection and activate Antibody-dependent enhancement including upregulation of cytokines and chemokines MiddleEastrespiratorysyndromecoronavirus disease from Saudi Arabia: a descriptive study Amurinevirus(JHM) causing disseminated encephalomyelitis with extensive destruction of myelin: II Active monitoring of persons exposed to patients with confirmed COVID-19 -United States Pneumonia of unknown etiology in Wuhan, China: potential for international spread via commercial air travel ModularorganizationofSARScoronavirus nucleocapsid protein Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumoniainWuhan, China: a descriptive study Emerging coronaviruses: genome structure, replication, and pathogenesis coronavirus: where we are and what we know Features, Evaluation and Treatment Coronavirus (COVID-19) Should scientists infect healthy people with the coronavirus to test vaccines? Convalescent plasma as a potential therapy for COVID-19 Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection The clinical pathology of severe acute respiratory syndrome (SARS): a report from Coronavirus vaccine clinical trial starting without usual animal data Human challenge studies to accelerate coronavirus vaccine licensure Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools Exploring the mechanism of liver enzyme abnormalities in patients with novel coronavirusinfected pneumonia Clinical characteristics of 2019 novel coronavirus infection in China COVID-19: gastrointestinal manifestations and potential fecal-oral transmission The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health-The latest 2019 novel coronavirus outbreak in Wuhan Clinical features of patients infected with 2019 novel coronavirus in Use of chest CT in combination with negative RT-PCR assay for the 2019 novel coronavirus but high clinical suspicion Exhaled air dispersion during high-flow nasal cannula therapy versus CPAP via different masks The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice Persistence of coronaviruses on inanimate surfaces and its inactivation with biocidal agents Outbreak of Pneumonia of Unknown Etiology in Wuhan China: the Mystery and the Miracle Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV A major outbreak of severe acute respiratory syndrome in Hong Kong Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic Genetic heterogeneity and risk of acute respiratory distress syndrome Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of Middle East respiratory syndrome coronavirus infection in the United Arab Emirates Practical Measures to Prevent COVID-19: A Mini-Review Importation and human-to-human transmission of a novel coronavirus in Vietnam Phylogenetic network analysis of SARS-CoV-2 genomes The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study Genomic Characterization of a Novel SARS-CoV-2 Evolutionary Trajectory for the Emergence of Novel Coronavirus SARS-CoV-2 Epidemiology, genetic recombination, and pathogenesis of coronaviruses A review of coronavirus disease-2019 (COVID-19) Castrucci Maria Rita , ListaFlorigio , on behalf of ISS COVID-19 study group . Whole genome and phylogenetic analysis of two SARS-CoV-2 strains isolated in Italy in Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect? Acute respiratory distress syndrome Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications On the origin and continuing evolution of SARS-CoV-2.NatlSci Rev Genetic diversity and evolution of SARS-CoV-2.Infection Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan Clinical Characteristics of Coronavirus Disease 2019 in China Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China Discovery of seven novel Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and delta coronavirus Pathological findings of COVID-19 associated with acute respiratory distress syndrome Evidence for gastrointestinal infection of SARS-CoV-2 Epidemiology, Pathogenesis, and Control of COVID-19 A novel coronavirus from patients with pneumonia in China Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia SARS-CoV-2 viral load in upper respiratory specimens of infected patients